Harbor Capital Advisors, Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

Harbor Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$27.21 - $39.48 $143,070 - $207,585	5,258 Added 24.37%	26,832 $767,000
Q4 2023 Jan 08, 2024	BUY	$21.2 - $31.03 $30,506 - $44,652	1,439 Added 7.15%	21,574 $660,000
Q3 2023 Oct 20, 2023	BUY	$26.2 - $36.08 $75,456 - $103,910	2,880 Added 16.69%	20,135 $541,000
Q2 2023 Jul 11, 2023	BUY	$25.16 - $41.38 $40,079 - $65,918	1,593 Added 10.17%	17,255 $615,000
Q1 2023 Apr 26, 2023	SELL	$23.68 - $38.51 $34,572 - $56,224	-1,460 Reduced 8.53%	15,662 $397,000
Q4 2022 Jan 20, 2023	SELL	$28.0 - $40.56 $10,276 - $14,885	-367 Reduced 2.1%	17,122 $0
Q3 2022 Oct 28, 2022	SELL	$29.63 - $48.31 $56,593 - $92,272	-1,910 Reduced 9.85%	17,489 $578,000
Q2 2022 Jul 26, 2022	SELL	$27.79 - $50.61 $33,431 - $60,883	-1,203 Reduced 5.84%	19,399 $683,000
Q1 2022 Apr 28, 2022	SELL	$39.62 - $69.97 $188,432 - $332,777	-4,756 Reduced 18.76%	20,602 $947,000
Q4 2021 Feb 04, 2022	BUY	$58.09 - $82.51 $1.47 Million - $2.09 Million	25,358 New	25,358 $1.68 Million

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.